Answers are grounded in this paper and cite their sources.
In situ cancer nanovaccine inhibits triple-negative breast cancer recurrence and metastasis, suggesting improved immunotherapy strategies.
In situ cancer vaccine is a new method for cancer immunotherapy, however, the local immunosuppressive microenvironment of cancer tissue limits its immune response and therapeutic efficacy. The CXCL12/CXCR4 axis plays a key role in forming an immunosuppressive microenvironment. In this study, siCXCR4 (S) was used as an "immune adjuvant" and co-loaded with hydroxycamptothecin (HCPT) to develop an in situ cancer nanovaccine (HCPT/S@CaP/HA) for synergistically inhibiting the growth, recurrence and metastasis of triple negative breast cancer (TNBC). HCPT/S@CaP/HA actively targeted to orthotopic TNBC cells and cancer-associated fibroblasts (CAFs), induced the immunogenic death of orthotopic TNBC cells to promote the maturation of dendritic cells (DCs). Meanwhile, HCPT/S@CaP/HA also reduced the secretion of CXCL12 by CAFs and silenced the expression of CXCR4 in TNBC tissue to bidirectionally block the CXCL12/CXCR4 axis, thereby synergistically reversing immunosuppressive microenvironment, enhancing the infiltration and activity of cytotoxic T lymphocytes in orthotopic TNBC tissues, and subsequently inhibiting the growth of orthotopic TNBC. Moreover, HCPT/S@CaP/HA inhibited the recurrence of TNBC by synergistically increasing the percentage of memory T lymphocytes in the spleen tissue of mice, and it diminished the spontaneous lung metastasis of orthotopic TNBC by promoting the presentation of TNBC antigens and activating TNBC-specific immune responses immune responses. HCPT/S@CaP/HA is a potential in situ cancer nanovaccine for the immunotherapy of TNBC.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: